"10.1371_journal.pone.0024718","plos one","2011-09-08T00:00:00Z","Oliver Frey; Lisa Bruns; Lars Morawietz; Kyri Dunussi-Joannopoulos; Thomas Kamradt","Institute of Immunology, Jena University Hospital, Jena, Germany; Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany; Institut of Pathology, Charit√© University Hospital Berlin, Berlin, Germany; Pfizer Research, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: OF LB TL. Performed the experiments: OF LB LM. Analyzed the data: OF LB LM TK. Contributed reagents/materials/analysis tools: KD-J LM. Wrote the paper: OF LB LM KD-J TK.","The authors have read the journal's policy and have the following conflicts. CD22-cal is a preclinical research reagent provided from Pfizer (formerly Whyeth). KDJ is an employee of Pfizer Biotherapeutics Research and Development, Cambridge, USA. LB is now an employee of Merck, Darmstadt, Germany. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","09","Oliver Frey","OF",5,TRUE,3,3,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
